JP2017513842A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513842A5
JP2017513842A5 JP2016561879A JP2016561879A JP2017513842A5 JP 2017513842 A5 JP2017513842 A5 JP 2017513842A5 JP 2016561879 A JP2016561879 A JP 2016561879A JP 2016561879 A JP2016561879 A JP 2016561879A JP 2017513842 A5 JP2017513842 A5 JP 2017513842A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
atom
salt
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016561879A
Other languages
English (en)
Japanese (ja)
Other versions
JP6470310B2 (ja
JP2017513842A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/061651 external-priority patent/WO2015156417A1/en
Publication of JP2017513842A publication Critical patent/JP2017513842A/ja
Publication of JP2017513842A5 publication Critical patent/JP2017513842A5/ja
Application granted granted Critical
Publication of JP6470310B2 publication Critical patent/JP6470310B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016561879A 2014-04-11 2015-04-09 シクロプロパンアミン化合物およびその用途 Expired - Fee Related JP6470310B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014082057 2014-04-11
JP2014082057 2014-04-11
PCT/JP2015/061651 WO2015156417A1 (en) 2014-04-11 2015-04-09 Cyclopropanamine compound and use thereof

Publications (3)

Publication Number Publication Date
JP2017513842A JP2017513842A (ja) 2017-06-01
JP2017513842A5 true JP2017513842A5 (https=) 2018-05-24
JP6470310B2 JP6470310B2 (ja) 2019-02-13

Family

ID=53055078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561879A Expired - Fee Related JP6470310B2 (ja) 2014-04-11 2015-04-09 シクロプロパンアミン化合物およびその用途

Country Status (28)

Country Link
US (9) US10053456B2 (https=)
EP (1) EP3129369A1 (https=)
JP (1) JP6470310B2 (https=)
KR (1) KR102359836B1 (https=)
CN (1) CN106459024B (https=)
AR (1) AR099994A1 (https=)
AU (1) AU2015244698B2 (https=)
BR (1) BR112016023382B1 (https=)
CA (1) CA2945085C (https=)
CL (1) CL2016002573A1 (https=)
CR (1) CR20160485A (https=)
DO (1) DOP2016000273A (https=)
EA (1) EA034197B1 (https=)
EC (1) ECSP16087256A (https=)
IL (1) IL248181B (https=)
MA (1) MA39732A (https=)
MX (1) MX375990B (https=)
MY (1) MY180575A (https=)
NZ (1) NZ725262A (https=)
PE (1) PE20161441A1 (https=)
PH (1) PH12016502016B1 (https=)
SG (2) SG10201808780YA (https=)
TN (1) TN2016000418A1 (https=)
TW (1) TWI669291B (https=)
UA (1) UA122205C2 (https=)
UY (1) UY36071A (https=)
WO (1) WO2015156417A1 (https=)
ZA (1) ZA201607773B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373103B (es) 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
AR099994A1 (es) 2014-04-11 2016-08-31 Takeda Pharmaceuticals Co Compuesto de ciclopropanamina y sus usos
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
ES2973286T3 (es) 2014-11-26 2024-06-19 St Europeo Di Oncologia S R L Modelos de trastornos del desarrollo neurológico basados en la reprogramación y usos de los mismos
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
CA2987876A1 (en) 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
JP6916795B2 (ja) 2015-12-29 2021-08-11 ミラティ セラピューティクス， インコーポレイテッド Ｌｓｄ１阻害剤
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
JPWO2017130933A1 (ja) * 2016-01-25 2018-11-29 国立大学法人 熊本大学 神経変性疾患治療剤
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
JP6999574B2 (ja) 2016-04-22 2022-01-18 インサイト・コーポレイション Ｌｓｄ１阻害剤の製剤
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
WO2018083138A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
MX2020001323A (es) 2017-08-03 2020-03-20 Oryzon Genomics Sa Metodos para tratar alteraciones del comportamiento.
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN109553591B (zh) * 2019-01-15 2020-12-15 山东安信制药有限公司 一种富马酸喹硫平中间体的制备方法
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
ES3053813T3 (en) 2019-03-20 2026-01-26 Oryzon Genomics Sa Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
CN117529325A (zh) * 2021-04-21 2024-02-06 纳特科药品有限公司 制备7-(吗啉基)-2-(N-哌嗪基)甲基噻吩并[2,3-c]吡啶衍生物的改进方法
CN113512031B (zh) * 2021-07-01 2024-01-30 都创(上海)医药开发有限公司 一种lsd1酶抑制剂tak-418中间体化合物制备方法
CN117164465B (zh) * 2023-09-04 2025-07-01 郑州大学 一种苯基环丙胺类化合物及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0210391A (pt) 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
CN101445469B (zh) 2003-09-24 2013-02-13 梅特希尔基因公司 组蛋白脱乙酰基酶抑制剂
JP2007516982A (ja) 2003-12-15 2007-06-28 日本たばこ産業株式会社 シクロプロパン化合物及びその医薬用途
EP2361242B1 (en) * 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
JPWO2010143582A1 (ja) * 2009-06-11 2012-11-22 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
CN102985402B (zh) 2010-04-20 2015-04-29 罗马大学 反苯环丙胺衍生物作为组蛋白去甲基酶lsd1和/或lsd2的抑制剂
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
JP2012036124A (ja) 2010-08-06 2012-02-23 Nagoya City Univ Ｈｉｖ複製阻害剤
WO2012022047A1 (en) * 2010-08-20 2012-02-23 Tongji University Rod system for gradual dynamic spinal fixation
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
EA023143B1 (ru) * 2011-03-25 2016-04-29 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Замещенный циклопропиламин в качестве ингибитора lsd1
US20140296255A1 (en) 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
EP2741741A2 (en) * 2011-05-19 2014-06-18 Oryzon Genomics, S.A. Lysine demethylase inhibitors for inflammatory diseases or conditions
KR20140052018A (ko) 2011-08-09 2014-05-02 다케다 야쿠힌 고교 가부시키가이샤 시클로프로판아민 화합물
MX356344B (es) 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
RU2668952C2 (ru) 2011-10-20 2018-10-05 Оризон Дженомикс, С.А. (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
CN105051005B (zh) * 2012-10-12 2017-06-13 武田药品工业株式会社 环丙胺化合物及其用途
CN104042616B (zh) 2014-02-20 2016-08-24 复旦大学附属眼耳鼻喉科医院 赖氨酸特异性去甲基化酶1抑制剂的应用
AR099994A1 (es) * 2014-04-11 2016-08-31 Takeda Pharmaceuticals Co Compuesto de ciclopropanamina y sus usos
WO2015168149A2 (en) 2014-04-28 2015-11-05 Massachusetts Eye & Ear Infirmary Sensorineural hair cell differentiation

Similar Documents

Publication Publication Date Title
JP2017513842A5 (https=)
PE20161441A1 (es) Compuesto de ciclopropanamina y sus usos
AR063451A1 (es) Diazabiciclo alcanos como receptores nicotinicos de acetilcolina. composiciones farmaceuticas.
JP2014523851A5 (https=)
PH12019501707A1 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
JP2015509110A5 (https=)
CA2887598A1 (en) Cyclopropanamine compound and use thereof
JP2016505637A5 (https=)
JP2013517279A5 (https=)
JP2018516904A5 (https=)
JP2015516427A5 (https=)
PE20160859A1 (es) Inhibidores de la quinasa reguladora de la senal de apoptosis
AR099489A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
JP2010526106A5 (https=)
JP2013063968A5 (https=)
SI1919465T1 (en) GSK-3 INHIBITORS
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
HRP20191744T1 (hr) 1-[2-(aminometil)benzil]-2-tiokso-1,2,3,5-tetrahidro-4h-pirolo[3,2-d]pirimidin-4-oni kao inhibitori mijeloperoksidaze
JP2017500289A5 (https=)
JP2017505293A5 (https=)
JP2013539774A5 (https=)
RU2015101210A (ru) Производные тиофена, используемые для лечения сахарного диабета
JP2016540811A5 (https=)
JP2015516419A5 (https=)
EP3999181C0 (en) POLYMORPHS OF (R)-N-(5-(5-ISOPROPYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-METHYL-2H-TETRAZOLE-5-CARBOXAMIDE